ACR logo

Acrux Limited Stock Price

ASX:ACR Community·AU$5.7m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 19 Fair Values set on narratives written by author

ACR Share Price Performance

AU$0.014
-0.04 (-73.58%)
84.4% undervalued intrinsic discount
AU$0.09
Fair Value
AU$0.014
-0.04 (-73.58%)
84.4% undervalued intrinsic discount
AU$0.09
Fair Value
Price AU$0.014
AnalystConsensusTarget AU$0.09

ACR Community Narratives

AnalystConsensusTarget·
Fair Value AU$0.09 84.4% undervalued intrinsic discount

New Product Launches Including Cone 75% Will Expand Market Presence

1users have liked this narrative
0users have commented on this narrative
14users have followed this narrative

Recent ACR News & Updates

User avatar

New Product Launches Including Cone 75% Will Expand Market Presence

Expansion into niche markets and strategic licensing agreements are aimed at enhancing net margins and diversifying revenue streams.

Acrux Limited Key Details

AU$1.2m

Revenue

AU$2.3m

Cost of Revenue

-AU$1.1m

Gross Profit

AU$4.8m

Other Expenses

-AU$5.9m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-0.015
Gross Margin
-93.95%
Net Profit Margin
-499.58%
Debt/Equity Ratio
168.8%

Acrux Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Exceptional growth potential with slight risk.

4 Risks
2 Rewards

About ACR

Founded
1998
Employees
n/a
CEO
John Warmbrunn
WebsiteView website
www.acrux.com.au

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for the treatment of acne vulgaris; and Lidocaine and Prilocaine Cream USP, a topical anesthetic cream. It is also involved in the development of Efinaconazole, a topical solution used to treat fungal infections of toenails; Nitroglycerin 0.4%, an ointment for the treatment of pain associated with chronic anal fissure; and Acyclovir 5%, a cream for the treatment of cold sores. The company was incorporated in 1998 and is based in West Melbourne, Australia.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

Australian Market Performance

  • 7 Days: 1.2%
  • 3 Months: 5.0%
  • 1 Year: 9.1%
  • Year to Date: 9.2%
The market is up 1.2% over the last week, with the Materials sector leading the way, up 3.8%. In the last year, the market has climbed 9.1%. Looking forward, earnings are forecast to grow by 12% annually. Market details ›